Trial Profile
A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Heparin; Low molecular weight heparins; Vitamin K antagonists
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Pfizer
- 19 Dec 2022 Planned End Date changed from 30 Apr 2023 to 30 Apr 2024.
- 19 Dec 2022 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2024.
- 18 Jun 2020 Treatments section is updated to include one more dose range for an additional body weight window as- greater than or equal to 2.6kg will receive 0.1mg BID, and also PK sub-analysis part is introduced into the treatment with 2 new dose ranges as- "PK sub analysis, subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter". Eligibility criteria is updated to include minimum subject age as- new-born and minimum weight as 2.6 Kg instead of 28 days and 4 Kg respectively.